SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is currently the subject of intense retail speculation, with traders debating whether its recent price action represents a speculative bubble or a long-term opportunity, leading to volatile swings and high trading volume. The community is sharply divided, with some investors aggressively buying dips in anticipation of future index inclusion while others are betting on a significant correction, labeling it an overhyped IPO.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi LLC is trending as investors weigh conflicting visions for the company's future, with ongoing boardroom drama and proxy fighting clashing with community speculation regarding potential data center tenant deals. Market participants are intensely focused on unusual options activity and the strategic value of the firm's energy-infrastructure-heavy land holdings in Texas.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently a focal point for investors as a significant short interest faces potential pressure following strong Phase 3 clinical data for its gene-editing candidate. The community is actively debating the likelihood of a major pharmaceutical buyout and the implications of recent capital raising activities on the stock's future trajectory.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is facing intense volatility and selling pressure driven by market skepticism over potential acquisition targets and broader concerns regarding its long-term growth and content strategy. Investors are actively debating the effectiveness of the company's buyback program against recent deal-making attempts, with community sentiment deeply divided between those viewing the current valuation as a contrarian buying opportunity and others concerned about deteriorating sentiment and technical support levels.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending as investors debate its valuation and potential for a short squeeze, while also expressing significant frustration with management's communication and the stock's prolonged underperformance. The conversation is heavily focused on the company's rare disease gene therapy pipeline, the impact of recent clinical trial data, and speculation regarding a potential buyout.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending as investors focus on the company's confirmed single-trial pathway for AXPAXLI, with community discourse centered on the Q4 2026 NDA submission timeline and potential for future acquisition by major pharmaceutical players. While some investors express optimism regarding the regulatory de-risking event, others remain cautious, debating the long-term competitive impact of the data and the significance of recent trading volatility.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure is seeing massive volatility after the FDA rejected its Phase I/II data for its Huntington's disease gene therapy, mandating a new, randomized, sham-controlled trial instead of the expected accelerated approval path. The community is sharply divided, with frustrated investors debating the ethics of sham surgeries on terminal patients, while many are now bracing for significant delays and potential cash-burn concerns despite the company's existing capital runway.

Sezzle, Inc. engages in the operation of a digital payment platform that enables bank-to-bank transfer of money between consumers and businesses. The company was founded by Charlie G. Youakim, Killian Brackey and Paul V. Paradis on January 4, 2016 and is headquartered in Minneapolis, MN.

Sezzle Inc.

Sezzle is attracting significant attention as investors anticipate a potential short squeeze, fueled by high short interest and anticipation for the upcoming first-quarter earnings report. Community sentiment remains bullish, with many focusing on the company's strong fundamentals and perceived growth potential as a fintech super app, despite broader market volatility and recent board-level governance changes.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is trending due to a massive and unexpected sell-off, triggering intense community debate over whether the software sector is facing a long-term structural decline or an oversold buying opportunity. Investors are actively discussing the company's aggressive buyback program, recent acquisitions in the AI agent space, and the broader rotation out of software into speculative AI infrastructure as the primary drivers of this volatility.

CarMax, Inc. is a holding company, which engages in the retail of used vehicles and wholesale of vehicle auction operators. It operates through the CarMax Sales Operations and CarMax Auto Finance (CAF) segments. The CarMax Sales Operations segment consists of all aspects of its auto merchandising and service operations. The CAF segment pertains to its finance operation, which offers vehicle financing services to customers buying retail vehicles. The company was founded by Richard L. Sharp and William Austin Ligon in 1993 and is headquartered in Richmond, VA.

Carmax Inc

CarMax is experiencing significant volatility and downward pressure as shares hit multi-year lows following a leadership change and preliminary quarterly results that fell short of expectations. The community remains deeply divided, with bears pointing to systemic issues like rising subprime delinquencies and weak foot traffic, while bulls argue the stock is severely oversold and represents a deep-value opportunity for long-term patient investors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Co-Diagnostics Advances Latin American Commercialization Strategy for Co-Dx PCR Pro with Mexico Distributor Agreement

Co-Diagnostics Advances Latin American Commercialization Strategy for Co-Dx PCR Pro with Mexico Distributor Agreement Co-Diagnostics Advances Latin American Commercialization Strategy for Co-Dx PCR Pro with Mexico Distributor Agreement PR Newswire SALT LAKE CITY, June 11, 2026 Longstanding...

S&P 500, Nasdaq Close At Record Highs Amid Hopes Of Diplomatic Resolution Between US And Iran — MU, QCOM, LUNR, LLY, CODX In Focus

Equity

Investors remained hopeful about U.S.-Iran talks, offsetting recent military exchanges.

CODX Stock Explodes Over 630% In Six Sessions – Retail Traders Bet The Rally Isn’t Over Yet

Co-Diagnostics shares surged nearly 80% on Tuesday after the company expanded development efforts for a PCR test targeting the Bundibugyo strain of the Ebola virus.

Buybacks, Flybacks, and Comebacks

Wall Street’s speculative engine is running hot as investors pile into AI infrastructure, autonomous driving, biotech innovation, and advanced manufacturing plays driving some of the market’s biggest momentum stories. $HTT, $NTHI, $HLIT, $CODX, $RDW, $PONY, $MOD, $BAC, $STT, $BCS

Co-Diagnostics Advances Ebola PCR Assay Development Strategy with Joint Venture CoSara

Co-Diagnostics Advances Ebola PCR Assay Development Strategy with Joint Venture CoSara Co-Diagnostics Advances Ebola PCR Assay Development Strategy with Joint Venture CoSara PR Newswire SALT LAKE CITY, May 26, 2026 Joint development strategy has been developed to address international deployment...

Innovation Igniting into High-Growth Spotlight

As capital continues flowing into high-growth sectors tied to artificial intelligence, biotechnology, diagnostics, and defense technology, several emerging companies are rapidly capturing investor attention through financings, acquisitions, regulatory approvals, and platform expansion strategies. $SBFM, $TGNT, $CODX, $JUNS, $VIDA, $QUCY, $GFS, $GOOG, $MSFT, $NVDA

Co-Diagnostics Announces $3.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Co-Diagnostics Announces $3.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules Co-Diagnostics Announces $3.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules PR Newswire SALT LAKE CITY, May 19, 2026 SALT LAKE CITY, May 19, 2026 /PRNewswire/ --Co-Diagnostics, Inc...

These Stocks are Riding Some of the Hottest Narratives on Wall Street

Here are today’s most compelling market narratives. $NTHI, $AMST, $MTVA, $AGYS, $INM, $CODX

Diagnostic Platform Jumps as Ebola Response Readiness Takes Center Stage

Global public health systems have become increasingly focused on rapid diagnostic readiness since the COVID-19 pandemic exposed the risks of delayed outbreak detection and centralized testing bottlenecks. As emerging infectious disease threats continue to trigger international emergency responses, companies with the ability to quickly develop and deploy molecular diagnostic assays are drawing renewed investor attention.Shares of Co-Diagnostics, Inc. (NASDAQ: CODX) are surging Tuesday after the molecular diagnostics company announced it has completed the assay development strategy for the ...

Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.

Co-Diagnostics Inc

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$3.75
Prev Close	$3.84
Open	$3.73
Dividend Yield	0.00%
50-Day Moving Average	$3.14
Beta	1.07
Avg. Volume	16.55M
PE Ratio	-0.14

52-Week High	$1,395.00
52-Week Low	$1.26
Market Capitalization	$14.15M
EPS (Annual)	-$35.25
Price to Book	0.86
Revenue Per Employee	$3,636.57

CODXCo-Diagnostics Inc

Fundamentals

Feed

News

Sentiment

Fundamentals

Info

Latest CODX News